ZOLEDRONIC ACID FOR INJECTION CONCENTRATE SOLUTION

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Disponível em:

STRIDES PHARMA CANADA INC

Código ATC:

M05BA08

DCI (Denominação Comum Internacional):

ZOLEDRONIC ACID

Dosagem:

4MG

Forma farmacêutica:

SOLUTION

Composição:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG

Via de administração:

INTRAVENOUS

Unidades em pacote:

100

Tipo de prescrição:

Prescription

Área terapêutica:

BONE RESORPTION INHIBITORS

Resumo do produto:

Active ingredient group (AIG) number: 0141761002; AHFS:

Status de autorização:

APPROVED

Data de autorização:

2014-06-24

Características técnicas

Page
1
of
58
PRODUCT MONOGRAPH
PR
ZOLEDRONIC ACID FOR INJECTION CONCENTRATE
4 mg zoledronic acid/5 mL incorporated as the monohydrate for
intravenous infusion
BONE METABOLISM REGULATOR
Strides Pharma Canada Inc.
Date of Revision:
1565, Boul. Lionel-Boulet
August 11, 2020
Varennes, Quebec
Canada, J3X 1P7
Submission Control No.: 241322
Page
2
of
58
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
13
DRUG INTERACTIONS
.........................................................................................................
23
DOSAGE AND ADMINISTRATION
.....................................................................................
23
OVERDOSAGE
.......................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 28
STORAGE AND STABILITY
.................................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 32
PART II: SCIENTIFIC INFORMATION
...............................................................................
34
PHARMACEUTICAL INFORMATION
.................................................................................
34
CLINICAL TRIALS
.........................................